Tandem Diabetes Care, Inc. (NASDAQ: TNDM)

This lawsuit is for anyone who acquired securities in Tandem Diabetes Care, Inc. (NASDAQ: TNDM) from August 3, 2022 through November 2, 2022.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by issuing guidance downplaying the known risks to revenue that Company faced from increased competition and pandemic-related complications.

On November 2, 2022, Tandem revised its 2022 financial guidance downward, forecasting Non-GAAP sales of $800 to $805 million, down from $835 to $845 million. The Company attributed the revision to increased competition in the diabetes care sector, pandemic complications, and inflation. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Tandem Diabetes Care, Inc. (NASDAQ: TNDM) from August 3, 2022 through November 2, 2022 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.